Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where William H. Perloff is active.

Publication


Featured researches published by William H. Perloff.


American Journal of Obstetrics and Gynecology | 1959

Effect of prednisone on abnormal menstrual function.

William H. Perloff; Bertram J. Channick

Abstract Prednisone reduces or eliminates excess hair growth in women with idiopathic hirsutism 1 or, a preferable term, adrenal virilism. 2 While studying this phenomenon, we noted concurrent improvement in the menstrual status of patients with amenorrhea, menometrorrhagia, anovulation, and infertility. Intrigued by this desirable development, we treated women with menstrual abnormalities, with and without hirsutism, by this means, and the purpose of this paper is to report our observations.


American Journal of Obstetrics and Gynecology | 1951

Treatment of the surgical menopause with estradiol pellets at the time of operation.

Maurice L. Brown; Edward R. Lucente; J.Marsh Alesbury; William H. Perloff

Abstract 1.1. The results of implanting estradiol pellets in the abdominal wound at the time of operation in 38 consecutive, unselected patients undergoing hysterectomy and bilateral salpingo-oophorectomy are described. 2.2. Comparison with a control group of 37 patients shows that this procedure is an effective method of delaying, ameliorating, and perhaps eliminating the surgical menopause. 3.3. The major contraindications are discussed.


Journal of the American Geriatrics Society | 1956

THE ENDOCRINE TREATMENT OF CLIMACTERIC (STEROID-DEFICIENCY) OSTEOPOROSIS

William H. Perloff; Joseph H. Boutwell; Roberto Maas

The incidence of osteoporosis in the aged is unknown, but mounting evidence suggests that it is much more prevalent than has been realized. Not only is it often asymptomatic, but the diagnosis may be overlooked by the roentgenologist when density changes in the spine are slight. The recent report of GershonCohen et al. (1) describing asymptomatic and unrecognized vertebral fractures in the osteoporotic spines of the aged is interesting in this connection. Despite the classic observations of Albright and Reifenstein (2) that menopausal osteoporosis is primarily a disorder of the bony matrix and that the decalcification is secondary, and despite their demonstration of the beneficial effects of estrogen and androgen, most physicians are apparently unaware of the therapeutic improvements which result from the administration of these hormones. Recently Spencer et al. (3), employing a calcium tolerance test devised by Schilling and Laszlo (4), showed that patients with osteoporosis excreted a larger proportion of intravenously administered calcium than did normal individuals-once again proving the futility of treating this metabolic disorder with calcium. If osteoporosis be due to a steroid-hormone deficiency, why is it apparent in only certain postclimacteric patients, and why does it take so long to develop? What is the optimal therapeutic dose of estrogen and androgen, and why does clinical relief from pain occur so rapidly, whereas x-ray improvement takes many years? It was with the hope of answering these questions that the present study was undertaken.


American Journal of Obstetrics and Gynecology | 1950

Estradiol buccal tablets in the treatment of the menopause.

William H. Perloff

Abstract In this study of fifty menopausal women, the daily minimum effective dose of estradiol by the buccal route was essentially the same as that give intramuscularly as estradiol benzoate, or by pellet subcutaneously as compressed alpha-estradiol. One-sixth of this dose was required as ethinyl estradiol but five times as much was needed as alpha-estradiol when given orally. There were no untoward reactions reported to the buccal estradiol tablets by any of the fifty menopausal patients, and these tablets were generally preferred to other types of previously administered oral estrogens.


Postgraduate Medicine | 1951

Clinical management of a male pseudohermaphrodite.

William H. Perloff; Morris W. Brody

The authors describe a male pseudohermaphrodite who wanted to be more feminine in appearance and who was treated accordingly, both endocrinologically and surgically. The ramifications of such a regimen are discussed.


American Journal of Obstetrics and Gynecology | 1951

Treatment of the menopause. II

William H. Perloff

Abstract In a previous communication, 1 a large variety of estrogenic substances were compared regarding their effectiveness in relieving the symptoms of the menopause. It was manifestly impractical to study all the estrogens, so that only representative members of each of the large classes were employed. Since that time, two new oral estrogens have become commercially available, and the purpose of this study is to evaluate their clinical usefulness in similar fashion.


The Journal of Clinical Endocrinology and Metabolism | 1953

FEMALE PSEUDOHERMAPHRODISM: A DESCRIPTION OF 2 UNUSUAL CASES

William H. Perloff; Kyril B. Conger; Lester M. Levy


The Journal of Clinical Endocrinology and Metabolism | 1956

THYROTOXICOSIS FOLLOWING ACUTE THYROIDITIS: A REPORT OF 5 CASES

William H. Perloff


Fertility and Sterility | 1955

Some Aspects of the Chemical Nature of Human Ovarian Follicular Fluid

William H. Perloff; Julius Schultz; Edmond J. Farris; Howard Balin


American Journal of Obstetrics and Gynecology | 1949

Treatment of the Menopause

William H. Perloff

Collaboration


Dive into the William H. Perloff's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge